Alzheimer

Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist

by
blood-based biomarkers in neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, are a growing health concern worldwide, and their diagnosis and management are still challenging. However, recent advances in blood-based biomarkers offer new opportunities for clinical evaluation and monitoring of these diseases. In this review article, entitled “Blood Biomarkers in Neurodegenerative Diseases: Implications for the … Read more

Amyloid precursor protein βCTF accumulates in synapses in sporadic and genetic forms of Alzheimer’s disease

by
Amyloid precursor protein βCTF accumulates in synapses in sporadic and genetic forms of Alzheimer’s disease

Amyloid precursor protein βCTF accumulates in synapses in sporadic and genetic forms of Alzheimer’s disease The main pathological features observed in a brain with Alzheimer’s disease (AD) are the accumulation of β-amyloid (Aβ) peptides in the form of plaques and the aggregation of phosphorylated tau protein. Amyloid precursor protein (APP) can be processed via the amyloidogenic … Read more

The link between Alzheimer’s disease and Down syndrome

by
Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome

The link between Alzheimer’s disease and Down syndrome People with Down syndrome are genetically predisposed to developing Alzheimer´s disease. The strong association between Alzheimer disease and Down syndrome has a genetic basis through a gene-dose effect of the amyloid precursor protein (APP) gene located on chromosome 21, which is triplicated in this population. Consequently, neuropathologic changes associated with … Read more

Multimarker synaptic panels for FTD

by

Multimarker panels in FTD Frontotemporal dementia is the most common cause of early-onset dementia and the principal cause of FrontoTemporal Lobular Degeneration (FTLD). Approximately, 90–95% of FTLD cases are characterized by the accumulation in the brain of two different proteins – tau and transactive response DNA-binding protein-43 (TDP-43). These protein inclusions lead to a loss of … Read more

Stability of Alzheimer biomarkers in CSF

by
Alzheimer - Sant Pau Memory Unit - Barcelona

Alzheimer’s disease and its biomarkers in CSF Alzheimer’s disease is a chronic neurodegenerative disorder considered the most common cause of dementia in older people. Although clinical symptoms still form the core of diagnosis, imaging and cerebrospinal fluid biomarkers now play an important role in the diagnostic process. Two important neuropathological features of Alzheimer’s are the … Read more

Concordance between amyloid markers in CSF

by
Delaby Sant Pau Memory Unit - Barcelona

Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is considered a marker of amyloid pathology, a series of studies have shown that a decrease in CSF Aβ1-42 … Read more